ReviewInternational journal of molecular sciences2026
Insulin Intensification and Simplification Strategies in Patients with Type 2 Diabetes and Overweight or Obesity: A Scoping Review.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overweight and obesity complicate insulin treatment in adults with type 2 diabetes mellitus (T2DM), requiring consideration of glycaemic control, insulin requirements, body weight, and treatment burden. This scoping review mapped insulin treatment modification (ITM) strategies, synthesised their reported outcomes, and identified evidence gaps among insulin-treated adults with T2DM and overweight or obesity. Five electronic databases were searched following Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) and updated Joanna Briggs Institute methodological guidance. Thirty-three studies were classified into four ITM domains: add-on therapy to insulin, switching to advanced insulin formulations, simplifying complex insulin regimens with adjunctive therapy, and switching to fixed-ratio combinations. Intensification was generally studied in patients with higher baseline glycated haemoglobin or insulin requirements, whereas simplification was more often evaluated in those receiving complex insulin regimens. Insulin-dominant intensification generally increased total daily insulin dose, while intensification incorporating Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) or Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) commonly reduced insulin requirements and body weight. Simplification generally reduced insulin requirements and/or injection burden while maintaining or improving glycaemic control, with weight reduction frequently reported. Direct comparisons and obesity-specific subgroup analyses were limited. Intensification and simplification should therefore be considered complementary rather than opposing approaches, with outcomes influenced by therapeutic components and patient characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.